IDEXX Laboratories, Inc. (IDXX)
Market Cap | 42.04B |
Revenue (ttm) | 2.59B |
Net Income (ttm) | 497.48M |
Shares Out | 85.31M |
EPS (ttm) | 5.74 |
PE Ratio | 85.92 |
Forward PE | 75.76 |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 22 |
Last Price | $492.86 |
Previous Close | $496.44 |
Change ($) | -3.58 |
Change (%) | -0.72% |
Day's Open | 490.73 |
Day's Range | 490.00 - 498.98 |
Day's Volume | 329,402 |
52-Week Range | 182.94 - 513.20 |
These three healthcare stocks all had a good year in 2020, and their businesses look to have plenty of growth again in 2021.
Biden's administration plans to address climate change and take ESG initiatives. This call for investing in Shopify (SHOP), Magna International (MGA), IDEXX Lab (IDXX), Facebook (FB) and PayPa...
Rising pet ownership rates and a steadily increasing average household spending provide a powerful tailwind to this investment theme. Pet food, animal health, veterinary equipment, and special...
Earnings growth is considered the most important variable in influencing the share price. Notably, some of the stocks that boast of superb earnings growth include D.R.
WESTBROOK, Maine, Jan. 11, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing,...
After already rising over 109% since getting a checkup with the Wall Street vet, animal health care leader Idexx has bitten into a new buy zone. The post Breakout Stocks To Watch In 2021: Idex...
We have selected five MedTech growth stocks with further rooms for improvement in 2021.
If a Santa Claus rally grips Wall Street in the final days of December, the S&P 500 could see smart gains in 2020 despite the COVID-19 outbreak. These stocks helped the index to hit highs this...
Is (IDXX) Outperforming Other Medical Stocks This Year?
Americans love their pets, and no pandemic, not even the novel coronavirus, will change that, bolstering these eight pet stocks. The post 8 Pet Stocks That Will Make You Purr appeared first on...
IDEXX (IDXX) sees sturdy gains in CAG Diagnostics recurring revenues, supported by high organic gains in both U.S. and International markets.
Four large-cap MedTech stocks are currently flourishing on the back of several positive developments
Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Top Ranked Growth Stocks to Buy for December 14th
Here we pick five large cap stocks -- LB, TTD, IDXX, NVDA & CRWD -- that are well-poised to grow on solid fundamentals and gradual economic recovery.
Is (IDXX) Outperforming Other Medical Stocks This Year?
To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX Laboratories (IDXX).
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Americans treat pets like family members, and that includes spending on specialty food, health services, and insurance.
Idexx (IDXX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is (IDXX) Outperforming Other Medical Stocks This Year?
Americas CarMart (CRMT), Best Buy (BBY), IDEXX Laboratories (IDXX) and PerkinElmer (PKI) currently flaunt striking earnings growth and positive estimate revisions.
3 Best Buys from the Prospering Medical Instruments Industry
Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen U.S. SMID Company Growth Composite Po...
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
WESTBROOK, Maine, Nov. 12, 2020 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing,...
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
As of late, it has definitely been a great time to be an investor in IDEXX Laboratories (IDXX).
If you're interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip. The post Which Biotech Stocks Are a Buy on Earnings?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete ...
Final Trades: Caterpillar, Apollo, IDEXX & more
The "Halftime Report" traders give their top picks to watch for the second half.
IDEXX Laboratories, Inc. (IDXX) CEO Jay Mazelsky on Q3 2020 Results - Earnings Call Transcript
IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.
Idexx (IDXX) delivered earnings and revenue surprises of 19.01% and 7.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of IDEXX Laboratories (NASDAQ:IDXX) were unchanged after the company reported Q3 results.
Idexx Laboratories earnings and revenue growth were the best in years for the veterinary products supplier. Shares rose after closing in a buy zone.
WESTBROOK, Maine, Oct. 29, 2020 /PRNewswire/ -- Achieves revenue growth of 19% on a reported basis and 18% on an organic basis driven by Companion Animal Group Diagnostics recurring revenue gr...
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
IDEXX's (IDXX) third-quarter top line is likely to have benefited from strength in CAG and LPD businesses.
To get ready for earnings season, look for stocks in or near a potential buy range ahead of their next quarterly report. Idexx Laboratories currently fits that bill.
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (IDXX) Outperforming Other Medical Stocks This Year?
Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Chewy, Zoetis and FreshPet are just a couple of the names on our list of pet stocks to buy. Let's look at this growing industry more closely.
Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
About IDXX
IDEXX Laboratories, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practi... [Read more...]
Industry Diagnostics & Research | IPO Date Jun 21, 1991 |
CEO Jonathan Jay Mazelsky | Employees 9,200 |
Stock Exchange NASDAQ | Ticker Symbol IDXX |
Financial Performance
In 2019, IDXX's revenue was $2.41 billion, an increase of 8.75% compared to the previous year's $2.21 billion. Earnings were $427.72 million, an increase of 13.44%.
Analyst Forecasts
According to 9 analysts, the average rating for IDXX stock is "Buy." The 12-month stock price forecast is 500.60, which is an increase of 1.57% from the latest price.